| The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents F Spriano, EYL Chung, E Gaudio, C Tarantelli, L Cascione, S Napoli, ... Clinical Cancer Research 25 (16), 5167-5176, 2019 | 44 | 2019 |
| Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models E Gaudio, C Tarantelli, F Spriano, F Guidetti, G Sartori, R Bordone, ... Haematologica 105 (11), 2584, 2020 | 32 | 2020 |
| Abrogation of EMILIN1-β1 integrin interaction promotes experimental colitis and colon carcinogenesis A Capuano, E Pivetta, G Sartori, G Bosisio, A Favero, E Cover, ... Matrix Biology 83, 97-115, 2019 | 29 | 2019 |
| The extracellular matrix protein EMILIN1 silences the RAS-ERK pathway via α4β1 integrin and decreases tumor cell growth TME Modica, O Maiorani, G Sartori, E Pivetta, R Doliana, A Capuano, ... Oncotarget 8 (16), 27034, 2017 | 20 | 2017 |
| The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax C Tarantelli, E Gaudio, P Hillmann, F Spriano, G Sartori, L Aresu, ... Cancers 11 (6), 775, 2019 | 14 | 2019 |
| Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis AJ Arribas, S Napoli, L Cascione, G Sartori, L Barnabei, E Gaudio, ... Haematologica 107 (11), 2685, 2022 | 11 | 2022 |
| Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors AA Mensah, F Spriano, G Sartori, V Priebe, L Cascione, E Gaudio, ... Blood Advances 5 (10), 2467-2480, 2021 | 11 | 2021 |
| Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type V Priebe, G Sartori, S Napoli, EYL Chung, L Cascione, I Kwee, AJ Arribas, ... Cancers 12 (7), 1912, 2020 | 11 | 2020 |
| Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors F Guidetti, AJ Arribas, G Sartori, F Spriano, L Barnabei, C Tarantelli, ... Journal of Clinical Medicine 12 (2), 399, 2023 | 9 | 2023 |
| ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma G Sartori, S Napoli, L Cascione, EYL Chung, V Priebe, AJ Arribas, ... Journal of Experimental & Clinical Cancer Research 40 (1), 357, 2021 | 8 | 2021 |
| Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma A Arribas, S Napoli, L Cascione, E Gaudio, R Bordone-Pittau, M Barreca, ... European Journal of Cancer 138, S40, 2020 | 5 | 2020 |
| Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1α–STAT3 Axis T Virgilio, J Bordini, L Cascione, G Sartori, I Latino, D Molina Romero, ... Cancer immunology research 10 (12), 1525-1541, 2022 | 4 | 2022 |
| Understanding the mechanism of action of pyrrolo [3, 2-b] quinoxaline-derivatives as kinase inhibitors A Unzue, C Jessen-Trefzer, D Spiliotopoulos, E Gaudio, C Tarantelli, ... RSC Medicinal Chemistry 11 (6), 665-675, 2020 | 4 | 2020 |
| SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma A Stathis, U Mey, S Schär, F Hitz, C Pott, N Mach, F Krasniqi, U Novak, ... Blood advances 6 (13), 3911-3920, 2022 | 3 | 2022 |
| Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma S Napoli, L Cascione, A Rinaldi, F Spriano, F Guidetti, F Zhang, ... Haematologica 107 (5), 1131, 2022 | 3 | 2022 |
| Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma AJ Arribas, S Napoli, E Gaudio, L Cascione, AD Veroli, C Tarantelli, ... Molecular Cancer Therapeutics 18 (12_Supplement), A127-A127, 2019 | 3 | 2019 |
| The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib G Sartori, C Tarantelli, F Spriano, E Gaudio, L Cascione, M Mascia, ... British Journal of Haematology 204 (1), 191-205, 2024 | 1 | 2024 |
| ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells EYL Chung, G Sartori, M Ponzoni, L Cascione, V Priebe, ZY Xu‐Monette, ... British Journal of Haematology 203 (2), 244-254, 2023 | 1 | 2023 |
| ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms AJ Arribas, S Napoli, L Cascione, L Barnabei, G Sartori, E Cannas, ... bioRxiv, 2023.01. 01.522017, 2023 | 1 | 2023 |
| Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma F Spriano, G Sartori, C Tarantelli, M Barreca, G Golino, A Rinaldi, ... EJHaem 3 (3), 764-774, 2022 | 1 | 2022 |
